Zell am See buying MDMA pills

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Zell am See buying MDMA pills

Assessment of scientific support for each drug-diagnosis combination. Drug mentions are weighted estimates of national prescription drug occurrences based on observed medication use. Arch Intern Med. Background Unlike medicines prescribed for Food and Drug Administration—approved indications, off-label uses may lack rigorous scientific scrutiny. Despite concerns about patient safety and costs to the health care system, little is known about the frequency of off-label drug use or the degree of scientific evidence supporting this practice. Each reported drug-diagnosis combination was identified as Food and Drug Administration—approved, off-label with strong scientific support, or off-label with limited or no scientific support. Outcome measures included 1 the proportion of uses that were off-label and 2 the proportion of off-label uses supported by strong scientific evidence. Multivariate analyses were used to identify drug-specific characteristics predictive of increased off-label use. Conclusions Off-label medication use is common in outpatient care, and most occurs without scientific support. Efforts should be made to scrutinize underevaluated off-label prescribing that compromises patient safety or represents wasteful medication use. The Food and Drug Administration FDA focuses on market entry for prescription drugs rather than regulating physicians' prescribing practices, allowing off-label use of medications for indications beyond those formally evaluated by the manufacturer. Off-label prescribing of medications is legal, 1 often thought to be supported by scientific evidence, 2 and common in certain clinical settings. Despite sufficient evidence justifying some off-label practices, lack of FDA approval means that off-label uses are not given the same degree of scientific scrutiny as labeled indications. Scientific evidence documenting the efficacy of off-label uses in routine practice settings commonly falls short of what the drug's manufacturer would be required to provide the FDA to receive approval for that indication. Although regulation in this area is evolving, FDA policy prohibits direct-to-consumer promotion of drugs for unapproved uses and restricts such promotion to physicians. Previously published studies of off-label prescribing typically consider this practice in the context of narrowly defined clinical populations, including those with psychiatric disorders, 3 , 8 those with human immunodeficiency virus and AIDS, 9 children, 10 , 11 pregnant women, 12 and others commonly underserved by FDA-approved medicines. A study published in examined the most common uses of marketed medicines and found that 31 were for indications not initially approved by the FDA, of which 18 were not subsequently scrutinized. Using a nationally representative sample documenting physician prescribing by diagnosis, we examined the overall frequency and clinical circumstances of off-label prescription among commonly prescribed medications as a function of the strength of scientific support for those practices. We used a nationally representative survey of physician prescribing practices to examine off-label prescribing among office-based physicians in the United States. Observed drug uses were identified by clinical indication and determined to be labeled FDA approved , off-label lacking FDA approval with scientific evidence of therapeutic efficacy, or off-label without supporting evidence. Our analytic goals were to estimate the magnitude of off-label use, the most frequent conditions and drug classes contributing to off-label use, and whether observed off-label uses were supported by scientific evidence and to identify medication-specific characteristics predictive of this practice. Each quarter, approximately physicians report on each patient encounter during 2 randomly selected consecutive workdays. In , there were sampled patient-physician encounters with recorded medication therapy. For each patient encounter, physicians are instructed to record all diagnoses and indicate drug therapy specifically used to treat each diagnosis. Each patient encounter can generate multiple diagnoses, and there is direct correspondence between the recorded diagnosis and prescribed drug therapy. Physician-reported drug uses include new medications prescribed during that encounter or continued drug therapy that was previously ordered, even if no specific action was taken during that encounter. Drug uses are weighted to reflect national utilization patterns and referred to as drug mentions. This analysis considered commonly used medications, including the top by number of NDTI mentions, plus 60 additional randomly selected medications. Medications with over-the-counter availability in were excluded from this study. This strategy captured prescription medicines from a wide range of therapeutic contexts, but with a preponderance of antibiotics, hypertension therapies, and analgesics because of their prevalence as top sellers. Medications were identified by their chemical name, and drug mentions for proprietary and generic versions were combined to give the total mentions for that chemical when at least 1 version was in the original medication sample. The NDTI lists drug mentions stratified by the top 40 diagnoses associated with each medication. Diagnoses, coded using the International Classification of Diseases, Ninth Revision, Clinical Modification , 18 were grouped into 1 of the following 3 categories: FDA approved, off-label with strong scientific support, or off-label with limited or no scientific support. Diagnoses were considered FDA approved if they could be matched to the therapeutic indications reported in the drug's package insert as compiled in the Physicians' Desk Reference: 19 and assumed to be well supported by scientific evidence. Any diagnosis that could not be matched to a labeled indication was considered off-label. The degree of supporting evidence was assessed for each off-label indication treated with the medicines in our sample. We used the DRUGDEX system Thomson Micromedex, Greenwood Village, Colo , a nationally recognized pharmaceutical compendium that describes the efficacy and scientific documentation for labeled and off-label uses of prescription drugs 20 and that has been used to approve payment for off-label uses by Medicaid, 21 to create a database of scientifically supported but off-label indications for each drug in our sample. An indication was considered to be scientifically supported if, according to DRUGDEX, its effectiveness has been shown in controlled trials or observed in clinical settings. We found that indications our method classified as evidence-based were always supported by clinical trials, whereas those indications with little or no scientific support tended to rely on observational data or case reports. The Figure shows the strategy used to classify drug mentions by their level of scientific support. We were unable to separate patterns of use by the presence of comorbidities that might alter our assessment of whether the drug mention was for an off-label use. Because we were concerned that this might result in misclassification, we examined the comorbidities associated with congestive heart failure to gauge the magnitude of such misclassification. In this example, the concern is that substantial misclassification of angiotensin-converting enzyme inhibitors would result if congestive heart failure were to be reported frequently with other diagnoses for which angiotensin-converting enzyme inhibitors are often prescribed. Although we acknowledge this shortcoming, it seems unlikely to dramatically affect our findings. Drug-specific characteristics including therapeutic class, age, degree of promotion, use as a long- vs short-term therapy, form, and manufacturer were evaluated for their ability to predict off-label use. Medications were assigned to 1 of 13 mutually exclusive functional classes based on the therapeutic intent of its labeled indications. Approval date and patent exclusivity dates for each drug were obtained from the FDA's Electronic Orange Book, Vol: Food and Drug Administration 23 and used to calculate the drug's age and generic availability in year For medications available in multiple formulations, only that most commonly used in ambulatory settings was considered. Drugs were considered to have a high degree of promotion if they were among the 20 most heavily direct-to-consumer promoted drugs in Breadth of therapeutic definition was measured as the total number of approved indications reported in the Physicians' Desk Reference. The unit of analysis was the drug mention; the principle outcome measures were proportion and frequency of off-label prescription among sampled medications. We used multivariate regression to evaluate the ability of specific drug characteristics to predict off-label prescription. This allowed us to test several hypotheses: for example, that increased off-label prescription is associated with particular functional classes, use as a long-term therapy, older drug age, generic availability, a high degree of direct-to-consumer promotion, or manufacturer. The dependent variable was the counted number of drug mentions for off-label uses, and was transformed using a natural logarithm to normalize the distribution. Drugs from the same chemical class share many physical and therapeutic characteristics and, therefore, are not independent with regard to likelihood of prescription. To account for this lack of independence, models were fit clustering on the chemical class with robust variance estimates for the standard error. The NDTI reported an estimated million total drug mentions among the sampled drugs for year Substantial variation in off-label use was observed across functional classes. Off-label prescription with limited or no scientific support was more common than supported off-label use in all therapeutic classes except diabetes therapies. This is evident in Table 2 , which shows the top 5 medications by volume of off-label mentions, 3 of which albuterol sulfate, amoxicillin, and azithromycin were among the top 5 medications by overall use. Among medications with the highest proportions of off-label use, most lacked evidence of clinical efficacy. Conversely, off-label use for several medications was supported by a high degree of scientific evidence. It is not surprising, then, that 3 hypertension therapies losartan potassium, atenolol, and a combination of hydrochlorothiazide and metoprolol tartrate were among those medications with the highest degree of scientifically supported off-label use. Few drug-specific characteristics were associated with off-label prescription Table 3. Relative to analgesics, diabetes medications RR, 0. Other drug characteristics, including age, long-term use, combination therapies, formulation, dosing frequency, direct-to-consumer promotion, and manufacturer, showed few meaningful associations with off-label prescription. We believe that ours is the first study to systematically characterize the extent of off-label prescribing in general outpatient care. Many of the observed off-label drug mentions, particularly among medications frequently used off-label, represent a logical extension of the FDA-approved indication. For example, certain unapproved uses of antibiotics could be justified by laboratory studies demonstrating that the disease-causing organism responds to drug therapy. Albuterol, which is approved to treat asthma, is a clinically accepted off-label therapy for physiologically similar chronic obstructive pulmonary disease. In contrast, some of the observed off-label uses were as therapy for indications distinctly different from those for which the drug was approved. Examples include the use of metformin hydrochloride, approved for glycemic control in type 2 diabetes, as a therapy for relatively few patients with polycystic ovary syndrome and gabapentin, labeled for use as an anticonvulsant, as a widely used therapy for chronic nonspecific pain. Substantial heterogeneity remains in the degree to which many off-label practices, even those that seem to represent logical extensions of the labeled indication, are supported by scientific evidence. Our findings echo those of an earlier study conducted 2 decades ago that considered the degree of evidence supporting a drug's efficacy for a limited number of specific drug-indication pairs. We suggest that policy makers confront these issues by asking the following questions: 1 What kinds of data could inform our understanding of the clinical and economic implications of off-label and non—evidence-based prescribing? Differentiating off-label situations that are clinically reasonable from those that may be of concern is an essential first step. Such issues are at the forefront of prescription drug policy in Europe, where various systems have been established to monitor medication use after initial approval by regulatory authorities. In France, pharmacovigilance centers track postapproval prescribing of drugs, whereas the European Medicines Agency can require drug manufacturers to collect and analyze postapproval surveillance data and mandate license renewal at shorter time intervals. These examples are designed primarily to protect patient safety, although similar strategies could be used to inform judicious, evidence-based, and cost-effective prescribing choices. We need to know more about the factors that produce off-label medication use. Gabapentin drew substantial media attention, because its manufacturer was investigated and convicted for inappropriate marketing of off-label uses of the drug. Several limitations of this analysis should be noted. The sampled medications accounted for slightly more than half of all drug mentions in Patterns of use among these common medications may not be indicative of those for other drugs. Comorbidities, which were not accounted for in our analysis, could potentially explain some off-label uses, although the potential for misclassification bias remains small given the direct correspondence between diagnosis and medication. Similarly, we were unable to verify the use of many antibiotics as off-label without the results of supporting laboratory tests. Although these limitations may cause us to overestimate some off-label uses, others could cause off-label practices to be underestimated. For example, off-label uses defined by patient population were likely missed because these data were unable to account for patient characteristics such as age, sex, or pregnancy. Finally, we were limited in our ability to capture the gradient of evidence that exists for most off-label uses of the drugs in this sample. By establishing a high threshold for what is termed scientific support, the drug uses we identified as unsupported may have varying degrees of scientific evidence that fall short of this threshold. As is often the case with retrospective studies, we had to rely on data collected by others, primarily for different purposes. In these situations, we attempted to make conservative assumptions and consider how our results might have varied with somewhat different assumptions. Our main findings remained robust following such considerations. The ability to prescribe medicines off label brings greater latitude to turn scientific knowledge into innovative clinical practice. Although attention should be given to the situations where evidence-based off-label use is clinically beneficial, policy makers must begin to consider strategies for mandatory postapproval surveillance that focus on curtailing underevaluated off-label practices that jeopardize patient safety or represent economically wasteful prescribing practices. Correspondence: Randall S. Role of the Sponsor: None of the 3 supporting organizations played a role in the design and conduct of the study, analysis and interpretation of the data, or the preparation and approval of the manuscript. View Large Download. Table 1. Hoo GW Off label, on target? Nightingale SL Off-label use of prescription drugs. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. Off-label drug use in human immunodeficiency virus disease. Choonara IConroy S Unlicensed and off-label drug use in children: implications for safety. Accessed February 27, Payment for Covered Outpatient Drugs and Biologicals. Liang KZeger S Longitudinal data analysis using generalized linear models. Biometrika ; 22 Google Scholar Crossref. Long JErvin L Using heteroscedasticity: consistent standard errors in the linear regression model. Am Stat ; Google Scholar. Wilde Mathews A US gets dose of ideas on drug safety tactics from developed nations: in Europe and elsewhere, vigilance remains high in postapproval stage. Larkin M Warner-Lambert found guilty of promoting Neurontin off label. Save Preferences. Privacy Policy Terms of Use. This Issue. Citations View Metrics. X Facebook More LinkedIn. Original Investigation. May 8, David C. Finkelstein, MD ; Randall S. Stafford, MD, PhD. Data source. Sampled medications and observed diagnoses. Statistical analysis. Access your subscriptions. Access through your institution. Add or change institution. Free access to newly published articles. Purchase access. Rent article Rent this article from DeepDyve. Sign in to access free PDF. Save your search. Customize your interests. Create a personal account or sign in to:. Privacy Policy. Make a comment.

Off-label Prescribing Among Office-Based Physicians

Zell am See buying MDMA pills

Due to aggressive automated scraping of FederalRegister. If you are human user receiving this message, we can add your IP address to a set of IPs that can access FederalRegister. This process will be necessary for each IP address you wish to access the site from, requests are valid for approximately one quarter three months after which the process may need to be repeated. If you want to request a wider IP range, first request access for your current IP, and then use the 'Site Feedback' button found in the lower left-hand side to make the request. Request Access Due to aggressive automated scraping of FederalRegister.

Zell am See buying MDMA pills